牛牛AI助理已提取核心訊息
On February 7, 2024, Eli Lilly and Company, a pharmaceutical giant, announced the successful completion of a significant debt offering. The company entered into an underwriting agreement with major financial institutions including BofA Securities, Barclays Capital, Citigroup Global Markets, Deutsche Bank Securities, and Mizuho Securities USA. The offering comprised a total of $6 billion in notes with varying maturities ranging from 2027 to 2064 and interest rates from 4.500% to 5.100%. The transaction closed on February 9, 2024, with Eli Lilly netting approximately $6.45 billion after underwriting discounts and before offering expenses. The notes were issued under an existing indenture dated February 1, 1991. Eli Lilly has the option to redeem the notes at specified redemption prices and terms. The company specified that in the event of a default, the principal amount of the notes may become immediately due and payable.
On February 7, 2024, Eli Lilly and Company, a pharmaceutical giant, announced the successful completion of a significant debt offering. The company entered into an underwriting agreement with major financial institutions including BofA Securities, Barclays Capital, Citigroup Global Markets, Deutsche Bank Securities, and Mizuho Securities USA. The offering comprised a total of $6 billion in notes with varying maturities ranging from 2027 to 2064 and interest rates from 4.500% to 5.100%. The transaction closed on February 9, 2024, with Eli Lilly netting approximately $6.45 billion after underwriting discounts and before offering expenses. The notes were issued under an existing indenture dated February 1, 1991. Eli Lilly has the option to redeem the notes at specified redemption prices and terms. The company specified that in the event of a default, the principal amount of the notes may become immediately due and payable.
2024年2月7日，製藥巨頭禮來公司宣佈成功完成重大債券發行。該公司與包括美銀證券、巴克萊資本、花旗集團環球市場、德意志銀行證券和美國瑞穗證券在內的主要金融機構簽訂了承保協議。此次發行包括總額爲60億美元的票據，期限從2027年到2064年不等，利率從4.500％到5.100％不等。該交易於2024年2月9日完成，在承保折扣和發行費用之前，禮來公司的淨收入約爲64.5億美元。這些票據是根據1991年2月1日的現有契約發行的。禮來公司可以選擇按指定的兌換價格和條款兌換票據。該公司指出，如果發生違約，票據的本金可能會立即到期並支付。
2024年2月7日，製藥巨頭禮來公司宣佈成功完成重大債券發行。該公司與包括美銀證券、巴克萊資本、花旗集團環球市場、德意志銀行證券和美國瑞穗證券在內的主要金融機構簽訂了承保協議。此次發行包括總額爲60億美元的票據，期限從2027年到2064年不等，利率從4.500％到5.100％不等。該交易於2024年2月9日完成，在承保折扣和發行費用之前，禮來公司的淨收入約爲64.5億美元。這些票據是根據1991年2月1日的現有契約發行的。禮來公司可以選擇按指定的兌換價格和條款兌換票據。該公司指出，如果發生違約，票據的本金可能會立即到期並支付。
有用
沒用
